The German biotech is making headlines on two fronts this week — one that underscores its long-term oncology ambitions, and another that signals an increasingly aggressive posture in the courtroom. A fresh batch of six-year survival data for its personalized mRNA cancer vaccine has landed, while a newly filed patent lawsuit against Moderna adds another layer to the company’s legal strategy.
A Striking Survival Signal in Pancreatic Cancer
Seven out of eight patients remain alive six years after surgery for one of the deadliest malignancies on record. That is the headline from updated Phase 1 data on Autogene Cevumeran (BNT122), BioNTech’s individualized mRNA cancer vaccine, presented at the AACR Annual Meeting 2026. The trial, conducted jointly with Genentech, tracked patients with pancreatic ductal adenocarcinoma — a disease where the standard five-year survival rate hovers around 13 percent, according to the American Cancer Society.
The divergence between those who mounted an immune response and those who did not is stark. Among so-called responders, 87.5 percent were still alive at the last follow-up. In the non-responder group, only two of eight patients survived the same period, yielding a 25 percent survival rate and a median overall survival of 3.4 years. The median recurrence-free survival in the responder cohort has not yet been reached, while non-responders relapsed after a median of 13.4 months.
Perhaps the most compelling finding concerns durability. The T-cells triggered by the vaccine carry an estimated average lifespan of 7.7 years, suggesting the mRNA approach could enable long-term immunological surveillance against cancer recurrence. Each dose is custom-manufactured based on a patient’s tumor DNA profile, encoding up to 20 patient-specific neoantigens. A global Phase 2 trial is already underway.
Legal Escalation in the mRNA Arena
While the oncology pipeline generates scientific buzz, BioNTech is also sharpening its legal tools. Through CureVac — the Tübingen-based outfit it acquired last year — the Mainz group filed a patent infringement lawsuit in Delaware federal court on Friday. CureVac accuses Moderna of violating its intellectual property in the development of Spikevax, specifically regarding the stabilization of messenger RNA. The subsidiary is seeking licensing fees.
Should investors sell immediately? Or is it worth buying BioNTech?
This move follows a separate suit BioNTech itself filed in February targeting Moderna’s newer vaccine, mNEXSPIKE. The broader context: Moderna first sued Pfizer and BioNTech over Comirnaty in 2022, a case that remains unresolved. Other pharma heavyweights including GlaxoSmithKline, Bayer, and Alnylam Pharmaceuticals are also jostling for a slice of the historic revenue generated by COVID-19 vaccines. The outcome of these disputes will shape future revenue streams across the entire mRNA sector.
Stock Picture and What’s Ahead
BioNTech shares closed Friday at €88.75, a modest daily decline but up roughly 16 percent over the past month. The stock has now crept back above its closely watched 200-day moving average. The recent rally — nearly 19 percent over 30 days — follows a period of pressure tied to a lowered 2026 revenue forecast and the announced departure of both founders at year-end. The long-term cancer vaccine data should provide fundamental support for that recovery, though the stock still trades well below its 52-week high of €101.90.
Wall Street remains cautiously optimistic. Eighteen analysts rate the shares a consensus “Moderate Buy,” with an average price target of $133. The company is targeting 15 Phase 3 oncology studies running by the end of 2026, with up to seven late-stage clinical data packages expected this year — including Trastuzumab Pamirtecan, an HER2-directed antibody-drug conjugate. Meaningful oncology revenue is not anticipated until after 2026, but the goal of becoming a multi-product oncology company by 2030 remains intact.
Investors have two key dates on the calendar in May. First-quarter results are due on May 5, followed shortly by the annual general meeting, where a proposal to expand the supervisory board to eight members will be put to a vote — a move designed to bring deeper expertise in oncology and clinical development.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from April 27 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 27.
BioNTech: Buy or sell? Read more here...
